Literature DB >> 21496854

Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort.

Simon P Kim1, Angela L Alt, Christopher J Weight, Brian A Costello, John C Cheville, Christine Lohse, Cristine Allmer, Bradley C Leibovich.   

Abstract

PURPOSE: In 2010 the American Joint Committee on Cancer updated the renal cell carcinoma TNM classification. Without independent validation of the new classification its predictive ability for cancer specific survival and generalizability remains unknown. In this setting we determined the predictive ability of the 2010 TNM classification compared to that of the 2002 classification.
MATERIALS AND METHODS: Using the nephrectomy registry at our institution we retrospectively reviewed the records of 3,996 patients with unilateral or bilateral synchronous renal cell carcinoma treated with radical nephrectomy or nephron sparing surgery between 1970 and 2006. Cancer specific survival was estimated using the Kaplan-Meier method and predictive ability was evaluated using the concordance index.
RESULTS: There were 1,165 deaths (29.1%) from renal cell carcinoma a median of 1.9 years after surgery compared to a median followup of 7.4 years for survivors. The estimated 10-year cancer specific survival rate was 96%, 80%, 66%, 55%, 36%, 26%, 25% and 12% for patients with 2010 primary tumor classifications of pT1a, pT1b, pT2a, pT2b, pT3a, pT3b, pT3c and pT4, respectively (p <0.001). The multivariate concordance index for the 2002 and 2010 TNM classifications was 0.848 and 0.850, respectively.
CONCLUSIONS: The new 2010 classification remains a robust predictor of cancer specific survival compared to the 2002 classification by dividing pT2 lesions into pT2a and pT2b, reclassifying ipsilateral adrenal involvement as pT4, reclassifying renal vein involvement as pT3a and simplifying nodal involvement as pN0 vs pN1. However, the 2010 TNM classification showed only modest improvement in predictive ability compared to the 2002 classification.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21496854     DOI: 10.1016/j.juro.2011.02.059

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  51 in total

1.  Validation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance Index.

Authors:  Chunwoo Lee; Dalsan You; Junsoo Park; In Gab Jeong; Cheryn Song; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  Korean J Urol       Date:  2011-08-22

2.  Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database.

Authors:  Justin D Oake; Premal Patel; Luke T Lavallée; Jean-Baptiste Lattouf; Olli Saarela; Laurence Klotz; Ronald B Moore; Anil Kapoor; Antonio Finelli; Ricardo A Rendon; Jun Kawakami; Alan I So; Darrel E Drachenberg
Journal:  Can Urol Assoc J       Date:  2019-07-23       Impact factor: 1.862

Review 3.  Prognostic and Predictive Factors for Renal Cell Carcinoma.

Authors:  Cristina Suárez; Marc Campayo; Romà Bastús; Sergi Castillo; Olatz Etxanitz; Marta Guix; Núria Sala; Enrique Gallardo
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 4.  Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

Authors:  Nieves Martinez Chanza; Abhishek Tripathi; Lauren C Harshman
Journal:  Curr Treat Options Oncol       Date:  2019-05-03

5.  SOX2 and SOX12 are predictive of prognosis in patients with clear cell renal cell carcinoma.

Authors:  Weijie Gu; Beihe Wang; Fangning Wan; Junlong Wu; Xiaolin Lu; Hongkai Wang; Yao Zhu; Hailiang Zhang; Guohai Shi; Bo Dai; Dingwei Ye
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

6.  Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Authors:  Zhiyuan Lin; Li Liu; Yu Xia; Xiang Chen; Ying Xiong; Yang Qu; Jiajun Wang; Qi Bai; Jianming Guo; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

7.  Preoperative serum docosahexaenoic acid level predicts prognosis of renal cell carcinoma.

Authors:  Shinsuke Tasaki; Akio Horiguchi; Takako Asano; Kenji Kuroda; Akinori Sato; Junichi Asakuma; Keiichi Ito; Tomohiko Asano; Hirotaka Asakura
Journal:  Mol Clin Oncol       Date:  2016-05-09

8.  Allicin inhibits human renal clear cell carcinoma progression via suppressing HIF pathway.

Authors:  Bin Song; Ying Shu; Tianlei Cui; Ping Fu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

9.  Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy.

Authors:  Leonardo D Borregales; Dae Y Kim; Angie L Staller; Wei Qiao; Arun Z Thomas; Mehrad Adibi; Pheroze Tamboli; Kanishka Sircar; Eric Jonasch; Nizar M Tannir; Surena F Matin; Christopher G Wood; Jose A Karam
Journal:  Urol Oncol       Date:  2015-12-18       Impact factor: 3.498

10.  Application of the revised Tumour Node Metastasis (TNM) staging system of clear cell renal cell carcinoma in eastern China: advantages and limitations.

Authors:  Chao Qin; Li-Jiang Sun; Li Cui; Qiang Cao; Jian Zhu; Pu Li; Gui-Ming Zhang; Xin Mao; Peng-Fei Shao; Mei-Lin Wang; Zheng-Dong Zhang; Min Gu; Wei Zhang; Chang-Jun Yin
Journal:  Asian J Androl       Date:  2013-04-08       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.